PAIN MANAGEMENT IN PALLIATIVE CANCER PATIENTS: A PROSPECTIVE OBSERVATIONAL STUDY ON THE USE OF HIGH DOSAGES OF TRANSDERMAL BUPRENORPHINE

被引:3
|
作者
Clement, P. M. J. [1 ,2 ,3 ]
Beuselinck, B. [2 ,3 ]
Mertens, P. G. [2 ,3 ]
Cornelissen, N. [2 ,3 ]
Menten, J. [1 ,2 ,3 ]
机构
[1] KULeuven, Dept Oncol, Louvain, Belgium
[2] Leuven Canc Inst, Louvain, Belgium
[3] Katholieke Univ Leuven Hosp, Dept Oncol & Palliat Care, B-3000 Louvain, Belgium
关键词
buprenorphine; cancer pain; palliative; transdermal; DOUBLE-BLIND; ORAL MORPHINE; EFFICACY; CARE; TOLERABILITY; MULTICENTER; FENTANYL; SAFETY;
D O I
10.2143/ACB.3141
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Despite guidelines and recommendations, a large proportion of patients with cancer still have inadequate pain control. Transdermal opioid administration can overcome problems such as swallowing and compliance, because only one application every three days is needed. Transdermal buprenorphine was documented to provide effective pain relief in cancer and non-cancer patients. A ceiling effect was described in animals at supratherapeutic dose levels. Objectives: This prospective observational pilot study was designed to explore the need for doses of transdermal buprenorphine beyond the recommended maximum dose of 140 mu g/h, in a cohort of palliative patients with cancer pain. Methods: 36 consecutive palliative patients with uncontrolled cancer pain were prescribed transdermal buprenorphine after having received adequate information on the disease, its evolution, the pain and the drug. They gave written informed consent for participation in this observational study. Pain intensity and use of breakthrough medication were registered by the patient and the health care provider. Results: Pain was judged to be satisfactory controlled, by the patient and the health care providers, in 21 of 28 evaluable patients at a dose lower than or equal to 140 mu g/h. The success rate was higher in the hospitalized patient group. The observation of adequate pain control in two patients treated with doses up to 210 mu g/h supports the hypothesis that buprenorphine dose titration above 140 mu g/h can be clinically effective and well tolerated. This also refutes the assumption of a clinically relevant ceiling effect. Conclusions: Transdermal buprenorphine controls cancer pain in the majority of palliative patients.
引用
收藏
页码:87 / 91
页数:5
相关论文
共 50 条
  • [21] Transdermal buprenorphine for the treatment of cancer pain: results from a multicenter, observational, post-marketing study in Spain (RELIEF study)
    Camps, Carlos
    Casinello, Javier
    Antonio Virizuela, J.
    Escobar, Yolanda
    Sanchez-Magro, Isabel
    Stern, Andres
    PAIN MANAGEMENT, 2011, 1 (06) : 513 - 522
  • [22] Adherence to ESMO guidelines on cancer pain management and their applicability to specialist palliative care centers: An observational, prospective, and multicenter study
    Carbonara, L.
    Casale, G.
    De Marinis, M. G.
    Bosetti, C.
    Valle, A.
    Carinci, P.
    D'andrea, M. R.
    Corli, O.
    PAIN PRACTICE, 2025, 25 (01)
  • [23] Postoperative Analgesia with Epidural Infusion of Buprenorphine Versus Transdermal Buprenorphine in Total Abdominal Hysterectomy: A Prospective Observational Cohort Study
    Krishnan, Anju
    Sajid, Binu
    Kutty, Rekha Krishnan
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2021, 15 (03)
  • [24] Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain
    Leppert, Wojciech
    Kowalski, Grzegorz
    ONCOTARGETS AND THERAPY, 2015, 8 : 3621 - 3627
  • [25] USE OF TRANSDERMAL FENTANYL FOR CANCER PAIN MANAGEMENT - REPLY
    MOSSER, KH
    AMERICAN FAMILY PHYSICIAN, 1993, 47 (04) : 730 - 730
  • [26] The use of transdermal buprenorphine in addicted patients with chronic pain during substitution treatment with methadone
    Stachowiak, Andrzej
    MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE, 2010, 2 (02): : 112 - 115
  • [27] Cancer Pain Management in Palliative Care Patients
    Tan, Hale Duran
    Kafali, Huelya
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2009, 31 (08) : 614 - 614
  • [28] Transdermal buprenorphine improves overall quality of life and symptom severity in cancer patients with pain
    Shen, Wen-Chi
    Hou, Ming-Mo
    Huang, Tai-Lin
    Wang, Cheng-Hsu
    Huang, Yen-Min
    Chen, Jen-Shi
    Chen, Mei-Ling
    JOURNAL OF CLINICAL NURSING, 2023, 32 (3-4) : 539 - 547
  • [29] Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study
    Safakish, Ramin
    Ko, Gordon
    Salimpour, Vahid
    Hendin, Bryan
    Sohanpal, Imrat
    Loheswaran, Gena
    Yoon, Sun Young Rosalia
    PAIN MEDICINE, 2020, 21 (11) : 3073 - 3086
  • [30] Methadone Rotation for Cancer Patients with Refractory Pain in a Palliative Care Unit: An Observational Study
    Rhondali, Wadih
    Tremellat, Flora
    Ledoux, Mathilde
    Ciais, Jean-Francois
    Bruera, Eduardo
    Filbet, Marilene
    JOURNAL OF PALLIATIVE MEDICINE, 2013, 16 (11) : 1382 - 1387